GlassScriptPhysician profile
John J Hembry
NPI 1508844309
$1,364.71
in general payments reported to CMS, 2019-2025
17 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.27 · 2024: $265 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,340.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $307.46 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $214.38 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $194.58 | 2024-2025 | Airsupra, Farxiga |
| Dexcom, INC. | $107.74 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $83.35 | 2025 | Repatha, Otezla |
| Abbvie INC. | $75.17 | 2025 | |
| Lilly USA, LLC | $69.79 | 2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $65.95 | 2025 | Auvelity, Symbravo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.58 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $46.56 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $34.89 | 2025 | Veozah |
| Lundbeck LLC | $24.03 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $20.82 | 2025 | |
| Merck Sharp & Dohme LLC | $19.12 | 2024 | Capvaxive, Vaxelis, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $18.59 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $17.73 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.97 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hembry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.